Maxcal-C (a polyherbal formulation) prevents ovariectomy-induced osteoporosis in rats

Abstract

Objectives:The aim of the present study was to investigate the anti-osteoporotic activity of Maxcal-C in ovariectomy (OVX)-induced osteoporosis in rats.Materials and Methods:Sham-operated control rats were designated as Group I; Group II animals served as OVX control; Group III OVX control rats treated with Calcium Sandoz (50 mg/kg, p.o.); Group IV and V OVX control rats treated with Maxcal-C (250 and 500 mg/kg, p.o.), respectively. All the aforementioned treatments were given for four weeks after the development of osteoporosis. At the end of the treatment, serum biochemical parameters such as serum calcium and alkaline phosphate were measured. After sacrificing the animals, femoral bone parameters with histology, body weight, and bone breaking strength of 5th lumbar vertebra were measured.Results:The treatment with Maxcal-C showed a significant improvement in serum biochemical, femoral bone parameters, and bone breaking strength of 5th lumbar vertebra with histopathological changes.Conclusion:The finding of the present study indicates that Maxcal-C showed a potential anti-osteoporotic activity. These results support the traditional use of Maxcal-C in the treatment of osteoporosis.

Effect of osteoporosis on fixation of osseointegrated implants in rats

“…From literature review, significant bone loss occurs from 4 to 8 weeks following ovariectomy in rats, depending on bone site examined and the technology applied. [19][20][21] It is reported that a loss of trabecular connection can be seen at 2 weeks following ovariectomy. 22 In this study, osteoporosis was induced and then a significant effect on trabecular bone was observed as early as 3 weeks after OVX surgery.…”

“…From literature review, significant bone loss occurs from 4 to 8 weeks following ovariectomy in rats, depending on bone site examined and the technology applied . It is reported that a loss of trabecular connection can be seen at 2 weeks following ovariectomy .…”

Inhibition of SLC7A11 by Sulfasalazine Enhances Osteogenic Differentiation of Mesenchymal Stem Cells by Modulating BMP2/4 Expression and Suppresses Bone Loss in Ovariectomized Mice

“…Osteoporosis is associated with severe complications, such as skeletal deformity and increased bone fractures; therefore, efficient treatments for osteoporosis are required urgently. (41) SAS promoted osteogenic differentiation of MSCs; therefore, it was used to treat our osteoporotic OVX mice. To our surprise, SAS treatment could alleviate the bone loss of OVX mice.…”